Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 10/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 10/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10629907 | 0.98 | ALDH1A1 (0.56) | ALDH1A1CHRNB2CHRNB4CHRNA4LMNA | |
| SCHEMBL5532786 | 0.98 | ALDH1A1 (0.56) | ALDH1A1CHRNB2CHRNB4CHRNA4LMNA | |
| SCHEMBL7390301 | 0.98 | ALDH1A1 (0.56) | ALDH1A1CHRNB2CHRNB4CHRNA4LMNA | |
| SCHEMBL8636451 | 0.98 | ALDH1A1 (0.56) | ALDH1A1CHRNB2CHRNB4CHRNA4LMNA | |
| SCHEMBL7389052 | 0.92 | — | — | |
| SCHEMBL131476 | 0.87 | ALDH1A1 (0.74) | ALDH1A1CHRNB2CHRNB4CHRNA4LMNA | |
| SCHEMBL3189950 | 0.84 | ALDH1A1 (0.70) | ALDH1A1CHRNB2CHRNB4CHRNA4LMNA | |
| SCHEMBL4056869 | 0.81 | — | — | |
| SCHEMBL9365362 | 0.81 | ALOX5 (0.47) | ALDH1A1KDM4AKDM4CKDM5AKDM7A | |
| SCHEMBL9361792 | 0.81 | ALOX5 (0.47) | ALDH1A1KDM4AKDM4CKDM5AKDM7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053961-A1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20110053961-A1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
| US-6001877-A | OF GIVEN FORMULA, WHICH ACTS AS AN ANTAGONIST OF LEUKOTRIENES; ADMINISTERING TO TREAT LEUKOTRIENE-B4 INDUCED DISEASES, SUCH AS ALLERGIES AND INFLAMMATION | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-12-14 | — | — | US | disclosed |
| US-5864039-A | THERAPEUTIC TREATMENT OF VARIOUS GASTROINTESTINAL DISEASES, CENTRAL NERVOUS DISORDERS, CARDIOVASCULAR DISORDERS, URINARY DISEASES, UROGENITAL DISORDERS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-01-26 | — | — | US | disclosed |
| EP-0873990-A1 | BENZOIC ACID COMPOUNDS AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-10-28 | — | — | EP | disclosed |
| US-5795914-A | Phenylalkan(en)oic acid | ONO PHARMACEUTICAL CO., LTD. (JP) | 1998-08-18 | — | — | US | disclosed |
| EP-0652208-B1 | Phenylalkan(en)oic acids with leukotriene B4 antagonistic activity | ONO PHARMACEUTICAL CO (JP) | 1998-01-14 | — | — | EP | disclosed |
| EP-0405116-B1 | Phenylalkan(en)oic acids | ONO PHARMACEUTICAL CO (JP) | 1995-12-06 | — | — | EP | disclosed |
| US-5457122-A | Leukotriene antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-10-10 | — | — | US | disclosed |
| EP-0652208-A1 | Phenylalkan(en)oic acids with leukotriene B4 antagonistic activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-05-10 | — | — | EP | disclosed |
| US-5256686-A | Antiinflammatory agent, antiallergens | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-10-26 | — | — | US | disclosed |
| US-5155104-A | Phenylalkan(en)oic acid | ONO PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| US-5086065-A | Leukotriene antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 1992-02-04 | — | — | US | disclosed |
| EP-0405116-A2 | Phenylalkan(en)oic acids | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053961-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, HPRT1, CXCR3 | ALDH1A1 699/4885CHRNB2 2342/4885CHRNB4 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.